192 related articles for article (PubMed ID: 27698933)
1. Screening of Pleural Mesotheliomas for DNA-damage Repair Players by Digital Gene Expression Analysis Can Enhance Clinical Management of Patients Receiving Platin-Based Chemotherapy.
Walter RF; Vollbrecht C; Werner R; Mairinger T; Schmeller J; Flom E; Wohlschlaeger J; Barbetakis N; Paliouras D; Chatzinikolaou F; Adamidis V; Tsakiridis K; Zarogoulidis P; Trakada G; Christoph DC; Schmid KW; Mairinger FD
J Cancer; 2016; 7(13):1915-1925. PubMed ID: 27698933
[TBL] [Abstract][Full Text] [Related]
2. miRNA regulation is important for DNA damage repair and recognition in malignant pleural mesothelioma.
Mairinger FD; Werner R; Flom E; Schmeller J; Borchert S; Wessolly M; Wohlschlaeger J; Hager T; Mairinger T; Kollmeier J; Christoph DC; Schmid KW; Walter RFH
Virchows Arch; 2017 Jun; 470(6):627-637. PubMed ID: 28466156
[TBL] [Abstract][Full Text] [Related]
3. MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.
Walter RF; Mairinger FD; Ting S; Vollbrecht C; Mairinger T; Theegarten D; Christoph DC; Schmid KW; Wohlschlaeger J
Br J Cancer; 2015 Mar; 112(5):883-90. PubMed ID: 25668009
[TBL] [Abstract][Full Text] [Related]
4. Mitogen signal-associated pathways, energy metabolism regulation, and mediation of tumor immunogenicity play essential roles in the cellular response of malignant pleural mesotheliomas to platinum-based treatment: a retrospective study.
Mathilakathu A; Borchert S; Wessolly M; Mairinger E; Beckert H; Steinborn J; Hager T; Christoph DC; Kollmeier J; Wohlschlaeger J; Mairinger T; Schmid KW; Walter RFH; Brcic L; Mairinger FD
Transl Lung Cancer Res; 2021 Jul; 10(7):3030-3042. PubMed ID: 34430345
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy.
Mairinger FD; Schmeller J; Borchert S; Wessolly M; Mairinger E; Kollmeier J; Hager T; Mairinger T; Christoph DC; Walter RFH; Eberhardt WEE; Plönes T; Wohlschlaeger J; Jasani B; Schmid KW; Bankfalvi A
Oncotarget; 2018 Apr; 9(32):22254-22268. PubMed ID: 29854276
[TBL] [Abstract][Full Text] [Related]
6. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.
Righi L; Papotti MG; Ceppi P; Billè A; Bacillo E; Molinaro L; Ruffini E; Scagliotti GV; Selvaggi G
J Clin Oncol; 2010 Mar; 28(9):1534-9. PubMed ID: 20177021
[TBL] [Abstract][Full Text] [Related]
7. Screening of Pleural Mesothelioma Cell Lines for Kinase Activity May Identify New Mechanisms of Therapy Resistance in Patients Receiving Platin-Based Chemotherapy.
Borchert S; Suckrau PM; Wessolly M; Mairinger E; Hegedus B; Hager T; Herold T; Eberhardt WEE; Wohlschlaeger J; Aigner C; Bankfalvi A; Schmid KW; Walter RFH; Mairinger FD
J Oncol; 2019; 2019():2902985. PubMed ID: 31929796
[TBL] [Abstract][Full Text] [Related]
8. A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma.
Zimling ZG; Sørensen JB; Gerds TA; Bech C; Andersen CB; Santoni-Rugiu E
Cancer Chemother Pharmacol; 2012 Nov; 70(5):743-54. PubMed ID: 22960937
[TBL] [Abstract][Full Text] [Related]
9. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin.
Zucali PA; Giovannetti E; Destro A; Mencoboni M; Ceresoli GL; Gianoncelli L; Lorenzi E; De Vincenzo F; Simonelli M; Perrino M; Bruzzone A; Thunnissen E; Tunesi G; Giordano L; Roncalli M; Peters GJ; Santoro A
Clin Cancer Res; 2011 Apr; 17(8):2581-90. PubMed ID: 21262916
[TBL] [Abstract][Full Text] [Related]
10. Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients.
Powrózek T; Kowalski DM; Krawczyk P; Ramlau R; Kucharczyk T; Kalinka-Warzocha E; Knetki-Wróblewska M; Winiarczyk K; Dyszkiewicz W; Krzakowski M; Milanowski J
Clin Lung Cancer; 2014 Nov; 15(6):455-65. PubMed ID: 25246386
[TBL] [Abstract][Full Text] [Related]
11. Low ERCC1 expression is a good predictive marker in lung adenocarcinoma patients receiving chemotherapy based on platinum in all TNM stages - a single-center study.
Piljić Burazer M; Mladinov S; Matana A; Kuret S; Bezić J; Glavina Durdov M
Diagn Pathol; 2019 Sep; 14(1):105. PubMed ID: 31521181
[TBL] [Abstract][Full Text] [Related]
12. Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT.
Schaefer NG; Veit-Haibach P; Soyka JD; Steinert HC; Stahel RA
Eur J Radiol; 2012 Jan; 81(1):e19-25. PubMed ID: 21129871
[TBL] [Abstract][Full Text] [Related]
13. Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival.
Zimling ZG; Sørensen JB; Gerds TA; Bech C; Andersen CB; Santoni-Rugiu E
J Thorac Oncol; 2012 Jan; 7(1):249-56. PubMed ID: 22031231
[TBL] [Abstract][Full Text] [Related]
14. [Prognosis related clinical and molecular factors in malignant pleural mesothelioma].
Wang YY; Zhang H; Bai H; Wang SH; Wu MN; An TT; Zhao J; Zhuo ML; Duan JC; Wang ZJ; Wang J
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar; 36(3):162-8. PubMed ID: 23856136
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer.
Pesta M; Kulda V; Fiala O; Safranek J; Topolcan O; Krakorova G; Cerny R; Pesek M
Anticancer Res; 2012 Nov; 32(11):5003-10. PubMed ID: 23155271
[TBL] [Abstract][Full Text] [Related]
17. The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection.
Kang CH; Jang BG; Kim DW; Chung DH; Kim YT; Jheon S; Sung SW; Kim JH
Lung Cancer; 2010 Jun; 68(3):478-83. PubMed ID: 19683826
[TBL] [Abstract][Full Text] [Related]
18. Poor Prognostic Factors in Patients with Malignant Pleural Mesothelioma Classified as Pathological Stage IB According to the Eighth Edition TNM Classification.
Takuwa T; Hashimoto M; Kuroda A; Nakamura A; Nakamichi T; Fukuda A; Matsumoto S; Kondo N; Hasegawa S
Ann Surg Oncol; 2018 Jun; 25(6):1572-1579. PubMed ID: 29616420
[TBL] [Abstract][Full Text] [Related]
19. Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy.
Sodja E; Knez L; Kern I; Ovčariček T; Sadikov A; Cufer T
Eur J Cancer; 2012 Dec; 48(18):3378-85. PubMed ID: 22795264
[TBL] [Abstract][Full Text] [Related]
20. DNA repair gene expression level in peripheral blood and tumour tissue from non-small cell lung cancer and head and neck squamous cell cancer patients.
Schena M; Guarrera S; Buffoni L; Salvadori A; Voglino F; Allione A; Pecorari G; Ruffini E; Garzino-Demo P; Bustreo S; Consito L; Bironzo P; Matullo G
DNA Repair (Amst); 2012 Apr; 11(4):374-80. PubMed ID: 22284908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
